Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia

Lilly

Status and phase

Completed

Phase 4

Conditions

Schizophrenia

Treatments

Drug: Aripiprazole

Drug: Olanzapine

Study type

Interventional

Funder types

Industry

Identifiers

NCT00103571

8928

F1D-US-HGLS

Details and patient eligibility

About

The purposes of this study are to assess similarities and differences in the efficacy (how well the drug works), safety, and side effects of olanzapine and aripiprazole in patients with schizophrenia, schizoaffective disorder, or schizophreniform disorder.

Sex

All

Ages

18 to 55 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients must have schizophrenia, schizoaffective disorder, or schizophreniform disorder
Patients must be agitated
Patients must display psychotic symptoms
Patients must be inpatients who are expected to stay in the hospital for at least 5 days
Patients must be 18 to 55 years of age

Exclusion criteria

Patients may not be hospitalized for greater than 72 hours prior to study start
Patients may not have received more than one dose of olanzapine or aripiprazole within 72 hours prior to study start
Patients may not be actively suicidal
Patients may not be diagnosed with substance-induced psychosis or substance dependence
Patients may not have acute, serious, or unstable medical conditions